Tablet

The goal of the current work is to use the wet granulation technology to make medication tablets using fenugreek extract. Additionally, research was done on the impact of sodium starch glycolate, a super disintegrant, on drug release and disintegration. Mucilage found in fenugreek extract slows down the disintegration of tablets, resulting in a slower release of the medication. Therefore, sodium starch glycolate was employed as a super disintegrant to enhance disintegration and, consequently, in vitro drug release. Wet granulation was used to make tablet formulations both with and without sodium starch glycolate. It was done to evaluate the granules' flow characteristics and characterize the physicochemical makeup of tablet formulations. The fundamental cause of fenugreek's antidiabetic effect is the alkaloid trigonelline, which is present in large amounts. For the treatment of diabetes, this study concludes that fenugreek seed extracts in tablet form with super disintegrants will be more desirable, useful, and therapeutically more effective than combining the plant components directly for a quicker commencement of action.

The aim of this research work was to Evaluation of Some Natural Polymer used as Sustained Release Matrix Tablet, any pharmaceutical formulation contains two ingredients one is the active ingredient and other is an excipients. An excipients help in the manufacturing of dosage form and it also improves physicochemical parameters of the dosage form. Polymers play an important role as excipients in any dosage form. They influence drug release and should be compatible, non-toxic, stable, economic etc. and develop a fixed Dose Combination product in a two different strength using same blend for both the strengths of tablet as a SR tablet formulation. In the tablet, Extended Release layer consist of Antihypertensive Drug belonging to class β-selective adrenergic blocking agent without partial agonist or membrane stabilizing properties. Extended release preparation provides sustained release and reduces the chances of tough related side effects. In selected cases of extended release preparation of this drug used in treatment of hypertension and congestive heart failure. The clinical studies have shown beneficial role of this drug as an extended release preparation. The main objective of the present study was to develop, formulate and evaluate a matrix tablet by using hydrophilic natural retardant polymers which would retard drug release in upper GI tract and should start releasing the drug when it reaches the alkaline environment of small intestine. Okara and Tramarind Gum Mucilage were investigated as the model hydrophilic retardant polymers. Wet granulation method was and nine batches of tablets were prepared. The prepared tablets were subjected for pharmacopoeial and non-pharmacopoeial evaluation parameters including loose and tapped bulk density, compressibility index, hausner ratio, angle of repose, friability, hardness, thickness, weight variation, % drug content and in-vitro drug release studies. It can be concluded that the combination of hydrophilic polymers that are retardant in nature are better suited for sustained and controlled drug delivery system than the hydrophilic polymer alone.

An accurate, simple, rapid and sensitive HPLC method has been developed for the determination of mebhydroline napadisylate in the tablet. The Chromatography was performed on a reversed phase C-18 column(150 mm × 4.6 mm id, 5μm) by isocratic elution, using a mobile phase of acetonitrile : ammonia 25% (80 : 20 v/v) at ambient temperature 25±5 °C and UV detection operates at 320 nm in an overall analysis time of about 10 min.The total retention time was 1.612 min with a flow rate of 1.0 ml/min. % 0f RSD values for precision is found to be 0.293 (< 2).The limits of detection (LOD) and quantification (LOQ) were 0.03µg/ml and 0.096133µg/ml, respectively. The correlation coefficient for Mebhydroline Napadisylate 0.9972 indicates linearity of the methods within the limits. The linear range of determination for Mebhydroline Napadisylate was 100-500μg/ml. However, the change in flow rate and column temperature also did not show any significant variance. The % recovery was found to be 99.70%-99.41%.  As per ICH guidelines the proposed method is fully validated and found to be linear over a workable drug concentration, accurate, precise and robust.  This HPLC method is selective, precise, and accurate and can be used for routine analysis of pharmaceutical preparation in industrial quality-control laboratories.

Lornoxicam is a non steroidal anti-inflammatory drug of oxicam class and it has the same side effects of this group when taken orally and has a relatively short plasma half-life (3 to 4 h) which makes it a good candidate for colon targeting. It could avoid the systemic side effects, enhance its low oral bioavailability due to hepatic first pass metabolism and delay drug release to target the colon. Eighteen tablet formulations of lornoxicam were prepared by wet granulation and coated with different polymers (pectin, chitosan, ethyl cellulose, cellulose acetate phthalate, eudragit L-100 and eudragit L-100-55), each at three concentration. The tablets were evaluated for their physical characters, in–vitro dissolution in gradient pH, as well as, mathematical modeling using DDSolver software package. The dissolution data best fitted to first order with Tlag model with Krosmyer Pepas (n) values around unity suggesting erosion mechanism for all tablets except pectin coated ones which showed Fickian diffusion mechanism. Fitting the release data to the different erosion models suggested heterogeneous erosion mechanism. Lornoxicam tablets coated with 6% Eudragit L-100 were successfully delivered to the colon with a relative bioavailability of 531.96% compared to the conventional commercial tablets in rabbits.